Drug Trial Radar · NCT06469411
Effect of PMSCs and Their Secretome for the Treatment of GvHD
Last checked: Nov 19, 2026Latest source record: Jun 21, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
60
Actual
Start
Jan 1, 2023
Primary completion
Jun 30, 2023
Study completion Jan 30, 2024
Sponsor
- Lead sponsor
- Tabriz University of Medical SciencesAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- SCARM Institute, Tabriz, Iran
- First posted
- Jun 21, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 16 years, up to 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
In this clinical trial study, 60 patients with GvHD referred to Shahid Qazi Hospital in Tabriz, were randomly divided into 2 intervention and control groups (n= 30 in each) that received secretome and distilled water by injection, respectively. The method of blinding was triple-blinded and all the names and personal information of the patients were coded at the time of data collection and remained completely confidential.
Conditions
- GVHD
Interventions
Secretome (set of substances released from the cell to its surroundings) of mesenchymal stem cells retrieved from the placenta (containing 400 microgram protein/ milliliter)Biological
Patients in the intervention arm received 6 doses of secretome of mesenchymal stem cells retrieved from the placenta (containing 400 microgram protein/ milliliter) 4 cc dissolved in albumin 20% every week for 6 weeks
4 cc distilled water dissolved in albumin 20%Other
Patients in the control arm received 6 doses of 4 cc distilled water dissolved in albumin 20% every week for 6 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Liver involvementTime frame: At the beginning of the study and 6 weeks after the intervention
- Intestine conditionTime frame: At the beginning of the study and 6 weeks after the intervention
- Skin rashTime frame: At the beginning of the study and 6 weeks after the intervention
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Abolfazl Barzegari
Tabriz, East Azerbaijan Province, Iran
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.